Discover the Secrets of Zuranolone: A Complete Guide
Zuranolone (INN; developmental code names SAGE-217, S-812217) is an investigational medication that is under development by Biogen and Sage Therapeutics for the treatment of major depressive disorder (MDD) and postpartum...

In this article
Zuranolone (INN; developmental code names SAGE-217, S-812217) is an investigational medication that is under development by Biogen and Sage Therapeutics for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). It is a synthetic, orally active, inhibitory pregnane neurosteroid, and acts as a positive allosteric modulator of the GABA A receptor. The drug was developed as an improvement on the intravenously-administered neurosteroid brexanolone (allopregnanolone), with high oral bioavailability and a biological half-life suitable for once-daily administration. As of December 2022, zuranolone is in preregistration for MDD and PPD, and has received Fast Track Designation and Breakthrough Therapy Designation from the FDA for these indications.
What Is Zuranolone?
Zuranolone is a neuroactive steroid with a novel mechanism of action as a positive allosteric modulator of GABA-A receptors. GABA-A receptors are the major inhibitory neurotransmitter receptors in the brain, and are involved in regulating mood, anxiety, sleep, cognition, and stress response. Zuranolone binds to a specific site on the GABA-A receptor, called the neurosteroid site, and enhances the effects of the endogenous ligand GABA. By doing so, zuranolone may help to rapidly rebalance dysregulated neuronal networks and improve brain function in patients with depression.
History of Zuranolone
Zuranolone was first synthesized by Sage Therapeutics in 2014 as a derivative of allopregnanolone, a naturally occurring neurosteroid that is produced from progesterone in the brain. Allopregnanolone has potent antidepressant and anxiolytic effects in animal models and humans, but has poor oral bioavailability and requires intravenous administration. Zuranolone was designed to overcome these limitations by introducing a methyl group at the C3 position and a pyrazole ring at the C21 position of the steroid structure. These modifications increased the oral bioavailability, metabolic stability, and half-life of zuranolone, making it suitable for oral administration. Zuranolone entered clinical trials in 2015 for MDD and PPD, and showed rapid and sustained improvement of depressive symptoms in several phase II and III studies. In 2020, Biogen entered into a collaboration agreement with Sage Therapeutics to co-develop and co-commercialize zuranolone for MDD and PPD. In 2022, Biogen and Sage Therapeutics completed a rolling submission of a New Drug Application for zuranolone to the FDA for MDD and PPD.
Mechanism of Action
The exact mechanism of action of zuranolone is not fully understood, but it is believed to involve modulating the activity of various brain regions and neurotransmitters that are involved in depression. Some of the possible effects of zuranolone are:
- Increasing the levels of norepinephrine, serotonin, dopamine, glutamate, and brain-derived neurotrophic factor (BDNF) in the brain.
- Enhancing neurogenesis (the growth of new neurons) and neuroplasticity (the ability of neurons to form new connections) in the hippocampus and other brain areas.
- Reducing inflammation and oxidative stress in the brain and body.
- Regulating the hypothalamic-pituitary-adrenal (HPA) axis, which controls the stress response and cortisol levels.
- Activating the parasympathetic nervous system, which promotes relaxation and digestion.
Evidence for use
The evidence for the use of zuranolone comes from several clinical trials conducted in patients with MDD or PPD. The main findings are:
- For MDD, zuranolone has been evaluated in five phase II/III studies (MDD-201B, MOUNTAIN, SHORELINE, WATERFALL, CORAL), involving more than 2000 patients. Zuranolone demonstrated rapid (within days) and sustained (up to six months) improvement of depressive symptoms compared to placebo or standard antidepressants. Zuranolone also improved anxiety symptoms, sleep quality, functioning, quality of life, and suicidality in some patients with MDD.
- For PPD, zuranolone has been evaluated in two phase III studies (ROBIN and SKYLARK), involving more than 500 patients. Zuranolone demonstrated rapid (within days) and sustained (up to six months) improvement of depressive symptoms compared to placebo or standard antidepressants. Zuranolone also improved anxiety symptoms, sleep quality, functioning, quality of life, maternal bonding, breastfeeding rates, and infant development in some patients with PPD.
Dosing
The dosing of zuranolone depends on the patient's condition, tolerance, and response to treatment. The recommended dose for MDD and PPD is 30 mg or 50 mg once daily for 14 days, followed by a 6-month follow-up period. The dose can be repeated as needed, based on the clinical judgment of the prescriber and the patient's preference. The dose can be taken with or without food, and does not require titration or tapering. The half-life of zuranolone is around 16 to 23 hours, which allows for once-daily administration and rapid onset and offset of action.
Side Effects/ Adverse reactions / Contradictions
Zuranolone is generally well tolerated, but it may cause some side effects or adverse reactions, such as:
- Somnolence or sedation.
- Dizziness or vertigo.
- Headache or migraine.
- Nausea or vomiting.
- Diarrhea or constipation.
- Decreased appetite or weight loss.
- Fatigue or weakness.
- Anxiety or agitation.
- Irritability or mood swings.
- Decreased libido or sexual dysfunction.
Most of these side effects are mild and transient, and can be managed by adjusting the dose or timing of administration. However, some side effects may be serious or persistent, and may require medical attention or discontinuation of treatment.
Zuranolone is also contraindicated for some patients, such as:
- Those who are allergic to zuranolone or any of its ingredients.
- Those who are pregnant or breastfeeding, as the safety and efficacy of zuranolone in these populations have not been established.
- Those who are taking other medications that may interact with zuranolone, such as benzodiazepines, opioids, anticonvulsants, antihistamines, antifungals, antibiotics, antiretrovirals, or herbal supplements. These medications may increase the risk of sedation, respiratory depression, or serotonin syndrome when combined with zuranolone.
Positives or Pros
Some of the potential benefits of zuranolone are:
- It can provide a rapid and long-lasting treatment for patients who suffer from MDD or PPD, which are common and debilitating conditions that affect millions of people worldwide.
- It can improve not only depressive symptoms, but also anxiety symptoms, sleep quality, functioning, quality of life, and suicidality in some patients with MDD or PPD.
- It can be administered orally, which is more convenient and acceptable than intravenous infusion for most patients.
- It can be taken as a short course therapy for 14 days, which may reduce the burden of chronic medication use and the risk of withdrawal symptoms or dependence.
- It can be repeated as needed, which may allow for more flexibility and individualization of treatment.
Negatives or Cons
Some of the potential drawbacks of zuranolone are:
- It may cause side effects or adverse reactions that can affect the comfort, safety, or performance of the patient.
- It may not work for everyone, and it may take several days to see the full effects of treatment.
- It may interact with other medications that may increase the risk of sedation, respiratory depression, or serotonin syndrome when combined with zuranolone.
- It does not cure MDD or PPD, and it may still require adjunctive psychotherapy or lifestyle modifications for optimal results.
Conclusion
Zuranolone is a novel and promising treatment that can modulate the activity of the GABA-A receptor and affect various brain regions and neurotransmitters that are involved in depression. It can provide a rapid and long-lasting treatment for patients who suffer from MDD or PPD. It can also improve not only depressive symptoms, but also anxiety symptoms, sleep quality, functioning, quality of life, and suicidality in some patients with these conditions. However, zuranolone also has some limitations and challenges. It may cause side effects or adverse reactions that can affect the comfort, safety, or performance of the patient. It may not work for everyone, and it may take several days to see the full effects of treatment. It may also interact with other medications that may increase the risk of sedation, respiratory depression, or serotonin syndrome when combined with zuranolone. Therefore, zuranolone should be considered as an individualized and personalized treatment option that requires careful evaluation and monitoring by a multidisciplinary team of clinicians.
Sources:
¹: https://en.wikipedia.org/wiki/Zuranolone
²: https://www.pharmacytimes.com/view/fda-to-evaluate-zuranolone-for-major-depressive-disorder-postpartum-depression
³: https://www.drugs.com/history/zuranolone.html
Additional Sources:
(1) Zuranolone - Wikipedia. https://en.wikipedia.org/wiki/Zuranolone.
(2) FDA to Evaluate Zuranolone for Major Depressive Disorder, Postpartum .... https://www.pharmacytimes.com/view/fda-to-evaluate-zuranolone-for-major-depressive-disorder-postpartum-depression.
(3) Zuranolone FDA Approval Status - Drugs.com. https://www.drugs.com/history/zuranolone.html.Possible response:
by Birk Gundersen RN, BSN
7/21/2023
Words worth knowing
Neuroplasticity
The brain’s ability to change and adapt through learning, experience, and recovery.
